<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160389</url>
  </required_header>
  <id_info>
    <org_study_id>PBI-200-103</org_study_id>
    <nct_id>NCT05160389</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, Three-Way, Crossover Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200 in Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pyramid Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pyramid Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-dose, open-label, randomized, three-way crossover study to assess the effect&#xD;
      of food on the absorption and bioavailability of PBI-200.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-dose, open-label, randomized, three-way crossover study to assess the effect&#xD;
      of food on the absorption and bioavailability of PBI-200, administered orally under fasted&#xD;
      and fed conditions.&#xD;
&#xD;
      The study will enroll 18 healthy adult volunteers to ensure study completion of at least 12&#xD;
      evaluable volunteers. The study will be conducted in 3 groups, with each group enrolling 6&#xD;
      volunteers. As this is a crossover study, each volunteer will serve as their own control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-dose, open-label, randomized, three-way crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Maximum Concentration [T(max)] of PBI-200</measure>
    <time_frame>7 days</time_frame>
    <description>Tmax will be determined from the observed plasma concentration data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve (AUC) of PBI-200 from time zero to the time of the last measurable concentration [AUC(0-t)]</measure>
    <time_frame>7 days</time_frame>
    <description>AUC, calculated using linear up/ log down trapezoidal method from time zero to time t, where t is the time of the last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of PBI-200 from time zero to infinity [AUC(0-inf)]</measure>
    <time_frame>7 days</time_frame>
    <description>AUC from time zero to infinity, AUC(0-inf) = AUC(0-t) + Ct/ kel, where kel is the terminal rate constant and Ct is the last measurable concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum observed drug concentration [T(max)]</measure>
    <time_frame>7 days</time_frame>
    <description>Time of the maximum observed drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life [T(1/2)]</measure>
    <time_frame>7 days</time_frame>
    <description>Apparent terminal elimination half-life, calculated as ln(2)/ kel.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Food Effect in Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be administered with water, after an overnight fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-fat Meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be administered with water, after an overnight fast, after which time a standard low-fat breakfast will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-fat Meal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug will be administered with water, after an overnight fast, after which time a standard high-fat breakfast will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PBI-200</intervention_name>
    <description>Single dose of PBI-200</description>
    <arm_group_label>Fasted</arm_group_label>
    <arm_group_label>High-fat Meal</arm_group_label>
    <arm_group_label>Low-fat Meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female between 18 and 55 years of age (inclusive).&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18 and 32 kg/mÂ² (inclusive).&#xD;
&#xD;
          -  Non-smoking/non-vaping, healthy, with no history of clinically relevant medical&#xD;
             illness.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant cardiovascular, pulmonary, respiratory,&#xD;
             hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurological, or psychiatric disease which, in the opinion of the Investigator, would&#xD;
             jeopardize the safety of the volunteer or impact the validity of the study results.&#xD;
&#xD;
          -  History of gastrointestinal/hepatobiliary or other surgery that may affect PK profiles&#xD;
             (i.e., hepatectomy, gastric, bypass, or digestive organ resection).&#xD;
&#xD;
          -  Intolerance to repeated venipuncture.&#xD;
&#xD;
          -  Smoking or use of tobacco products (including vaping) within 3 months prior to the&#xD;
             first study drug administration.&#xD;
&#xD;
          -  Have a positive drug/alcohol screen, or history or presence of alcoholism or drug&#xD;
             abuse within 6 months of first study drug administration.&#xD;
&#xD;
          -  Volunteers with a corrected QT using Fredericia's formula (QTcF) prolongation over 450&#xD;
             milliseconds at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Pyramid Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dir. Clinical Operations</last_name>
    <phone>877-319-0324</phone>
    <email>ClinicalTrials@Pyramidbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bio-Kinetic Clinical Applications</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Howitt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 3, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteer</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

